Surv‐CRM‐12 : A Bayesian phase I/II survival CRM for right‐censored toxicity endpoints with competing disease progression

enthalten in: Statistics in Medicine | 2022

von Andrillon, A. | Chevret, S. | Lee, S. | +1

Seamless phase I/II design for novel anticancer agents with competing disease progression

enthalten in: Statistics in Medicine | 2021

von Biard, L. | Lee, S. | Cheng, B.